

Sugammadex for reversing neuromuscular blockages after lung surgery A systematic review and meta-analysis

Jia-Li Yang, MD^a, Kuen-Bao Chen, PhD^{a,b}, Mei-Ling Shen, MD^c, Wei-Ti Hsu, MD^a, Yu-Wen Lai, BN^d, Chieh-Min Hsu, MD^{a,*}

Abstract

Background: This study determined whether sugammadex was associated with a lower risk of postoperative pulmonary complications and improved outcomes in lung surgeries.

Methods: A systematic literature search was conducted using PubMed, Embase, Web of Science, and the Cochrane Library from January 2000 to March 2022. The characteristics of lung surgeries using sugammadex treatment compared with control drugs and postoperative outcomes were retrieved. The primary outcome was estimated through a pooled odds ratio (OR) and its 95% confidence interval (CI) was identified using a random-effects model.

Results: From 465 citations, 7 studies with 453 patients receiving sugammadex and 452 patients receiving a control were included. The risk of postoperative pulmonary complication (PPCs) was lower in the sugammadex group than in the control group. Also, it showed that the effect of sugammadex on PPCs in the subgroup analysis was significantly assessed on the basis of atelectasis or non-atelectasis. Furthermore, subgroup analysis based on the relationship between high body mass index (BMI) and PPCs also showed that sugammadex had less occurrence in both the high BMI (defined as BMI \geq 25) and low BMI groups. No difference in length of hospital stay (LOS) between the two groups was observed.

Conclusion: This study observed that although reversing neuromuscular blockages with sugammadex in patients undergoing thoracic surgery recorded fewer PPCs and shorter extubation periods than conventional reversal agents, no difference in LOS, postanaesthesia care unit (PACU) stay length and chest tube insertion duration in both groups was observed.

Abbreviations: BMI = body mass index, CI = confidence interval, LOS = length of hospital stay, OR = odds ratio, PACU = postanaesthesia care unit, PPC = postoperative pulmonary complication, SMD = standard mean difference.

Keywords: enhanced recovery after surgery, lobectomy, lung surgery, meta-analysis, neostigmine, postoperative pulmonary complications, sugammadex, VATS

1. Introduction

During the administration of general anesthesia, muscle relaxants are used to facilitate the surgery processes. Subsequently, after surgery, reversal agents, such as acetylcholinesterase inhibitors or sugammadex, are administered to recover respiratory muscle power and remove the endotracheal tube. However, compared with acetylcholinesterase inhibitors, sugammadex is associated with a significantly faster reversal of neuromuscular blockade and shortened discharge from the odds ratio (OR) to the postanaesthesia care unit (PACU) in general surgeries.^[1-3] It has also been reported that patients receiving sugammadex had fewer side effects than those given neostigmine.^[4] In another recent study.^[5] no significant difference was observed between sugammadex and

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

neostigmine based on the risk of the composite postoperative pulmonary complications outcome. Nevertheless, the effect of sugammadex in reducing PPCs remains controversial.^[6,7]

Lung cancer is the leading cause of cancer deaths worldwide.^[8] The number of surgeries for benign lung tumors or cancers is also growing increasingly. Literature has reported PPC's prevalence in thoracic surgery.^[9,10] Specifically, however, patients undergoing thoracic surgery may be at a higher risk of incomplete neuromuscular recovery.^[11,12] Hence, a residual block is proposed to increase the incidence of prolonged lung atelectasis and PPCs. In these surgeries, even mild PPCs were associated with increased early postoperative mortality, ICU admissions and length of stay (ICU & hospital).^[13] Therefore, the reversal of neuromuscular blockade after lung surgery is essential.

How to cite this article: Yang JL, Chen KB, Shen ML, Hsu WT, Lai YW, Hsu CM. Sugammadex for reversing neuromuscular blockages after lung surgery: A systematic review and meta-analysis. Medicine 2022;101:39(e30876).

Received: 15 April 2022 / Received in final form: 30 August 2022 / Accepted: 31 August 2022

http://dx.doi.org/10.1097/MD.000000000030876

The authors have no funding and conflicts of interest to disclose.

JLY, and KBC contributed equally to this work.

^a Department of Anesthesiology, China Medical University Hospital, Taichung, Taiwan, ^b Department of Anesthesiology, College of Medicine, China Medical University, Taichung, Taiwan, ^c Department of Anesthesiology, Taichung Tzu-Chi Hospital, Taichung, Taiwan, ^d Department of Nursing, China Medical University Hospital, Taichung, Taiwan.

^{*}Correspondence: Chieh-Min Hsu, Department of Anesthesiology, China Medical University Hospital, 40447 No.2, Yude Rd., North Dist., Taichung City 40447, Taiwan (e-mail: jamin815@gmail.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Recently, using sugammadex after thoracic surgeries has become more common. However, the association between sugammadex reversal and avoidance of PPCs in thoracic surgery remains unclear. Therefore, this study evaluated the impact of sugammadex on postoperative outcomes of thoracic surgery. The first human study for sugammadex was conducted on healthy volunteers and published in 2005.^[14] Based on this fact, we searched databases from 2000.

2. Material and Methods

Details of the protocol for this systematic review and meta-analysis have been registered on PROSPERO (CRD42022321409).

2.1. Search strategy

Three authors (WT Hsu, CM Hsu, JL Yang) independently searched the PubMed, web of science, Cochrane library, and Embase databases for eligible publications from January 2000 to March 2022, using the following keywords: "thoracic surgery", "video-assisted thoracoscopy", "pneumonectomy", "lobectomy", "lung resection surgery", "thoracotomy", "wedge resection", "sugammadex", and "bridion". Only published prospective and retrospective cohort studies that reported using sugammadex compared with a control drug (neostigmine or other cholinesterase inhibitors) in lung surgery were included. However, reviews, editorials, letters to editors, case reports, commentaries, articles that did not specify the surgery type, articles whose full text was unavailable in the English language, irretrievable articles, and articles published before 2000 were excluded.

2.2. Data extraction

This systematic review and meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.^[15] First, 2 authors (JL Yang and ML Shen) independently evaluated the titles and abstracts, retrieved full text articles and selected the studies. Then, discrepancies were resolved by consulting the other 2 authors (KB Chen and CM Hsu).

Primary outcomes included PPCs and length of hospital stay (LOS). LOS was defined as the number of days from the date of surgery to discharge. However, secondary outcomes included postoperative extubation time, length of PACU stay, and duration of chest tube insertion. While extubation time was defined as the time from surgery end until the patient fulfilled the criteria for safe extubation, length of PACU stay was defined as the duration of stay in PACU from admission to discharge. Additionally, the duration of chest tube insertion was defined as the number of days from the date of surgery to the removal of the chest tube.

2.3. Methodological quality assessment

The methodological quality of all included studies was independently assessed by 2 authors (YW Lai and JL Yang) using the modified Jadad scale.^[16] The modified Jadad scale comprises eight items to evaluate randomization, blinding, withdrawals, dropouts, inclusion, and exclusion criteria, adverse effects and statistical analysis. The total score for each article was 0 to 8. A score lower than three means low quality of the trial.

2.4. Statistical analysis

All statistical analyses and meta-analyses were performed using the review manager 5 software (version 5.4, The Nordic Cochrane Centre, Copenhagen, Denmark). Subsequently, we performed a pairwise meta-analysis using an inverse variance

random-effect model according to the recommendations of the Cochrane Handbook^[17]; this was because some factors including differences in surgery type and outcome definitions may cause inter-study heterogeneity. Pooled effect estimates were also obtained by calculating the standard mean difference (SMD) in outcomes for continuous variables and ORs for dichotomous variables along with their respective 95% confidence intervals (CIs). Then, heterogeneity was assessed using the I square (I^2) statistics and the related P value. Additionally, subgroup meta-analyses for PPCs assessed with atelectasis and without atelectasis, evaluated with early postoperative chest radiographic abnormalities and postoperative hypoxic episodes and residual neuromuscular blockade were conducted for the potential sources of heterogeneity between studies. Afterward, another subgroup analysis was performed for the high body mass index (BMI) (defined as ≥ 25) and low BMI groups to examine whether BMI's treatment effect was affected. Lastly, sensitivity analyses were conducted to assess the robustness of the findings by excluding retrospective studies. We did not conduct a publication bias analysis because of the lower than ten studies reviewed in this meta-analysis.

A *P* value less than 0.05 was considered statistically significant for the analysis of effect sizes, and if the $I^2 > 50\%$, the heterogeneity was considered high.

2.5. Ethics and dissemination

The ethical approval was not necessary for this meta-analysis.

3. Results

3.1. Study characteristics

Among the 465 potentially relevant citations from literature searching, 7 studies (1 prospective cohort, 3 retrospective cohorts, 3 randomized controlled trials) were identified to meet our inclusion criteria. We illustrated the study selection process with a PRISMA flow diagram in Figure 1. This review included 905 patients. from the 7 studies, we observed that 453 patients received sugammadex (178, 39.3% female) and 452 patients received a control (189, 41.8% female). The studies included were conducted between 2017 and 2021. Detailed characteristics of the included studies are shown in Table 1. The analyzed PPCs included prolonged air leak, pneumonia, atelectasis,^[18,19,21,23] postoperative hypoxic episodes,^[12,22] early postoperative chest radiographic abnormalities^[20] and incidence of residual neuromuscular blockade during both tracheal extubation and PACU admission.^[12] The modified Jadad scores for the methodological quality assessment of each selected study are illustrated in Table 2.

3.2. Incidence of postoperative pulmonary complications

Seven studies were included in the meta-analysis of PPCs, with 453 patients receiving sugammadex and 452 receiving a control. Results showed statistically significant less complications in the sugammadex group. (OR: 0.45, 95% CI: 0.32-0.63, $P < .001, I^2 = 0\%$) (Fig. 2a) Subgroup analysis also showed that the sugammadex group had less occurrence in PPCs whether assessed with atelectasis (OR: 0.47, 95% CI: 0.30-0.76, P = .002) or without atelectasis (which assessed with early postoperative chest radiographic abnormalities, incidence of postoperative hypoxic episodes and residual neuromuscular blockade) (OR: 0.43, 95% CI: 0.26-0.69, P < .001). Finally, we conducted a subgroup analysis for the relationship between BMI (≥25 defined as high BMI) and the incidence of PPCs, which revealed a reduced occurrence of sugammadex in both the high BMI (OR: 0.42, 95% CI: 0.24–0.73, P = .002) and low BMI groups (OR: 0.47, 95% CI: 0.31–0.72, P < .001) (Table 3).




Figure 1. PRISMA diagram of the study selection process for the systemic review and meta-analysis.

3.3. Total length of hospital stay

Three studies were included in the analysis of total LOS, reporting 192 patients receiving sugammadex and 205 receiving a control. Results showed no difference in LOS between the 2 groups (SMD = -0.28, 95% CI; -0.81 to 0.25, P = .29, $I^2 = 81\%$) (Fig. 2b).

3.4. Extubation time

The four studies that assessed the time from surgery end to extubation showed that the sugammadex group was associated with a shorter extubation time (SMD –1.0; 95% CI: –1.74 to 0.28, P = .007, $I^2 = 93\%$) (Fig. 2c).

3.5. Total rocuronium dose administration

Five studies measured the total dose of rocuronium administered throughout the operation. Results of the meta-analysis indicated no significant difference between both reversal groups (SMD; 0.3; 95% CI:-0.05 to 0.81, P = .09, $I^2 = 85\%$) (Fig. 2d).

3.6. Length of PACU stay

Two studies were included that analyzed the length of PACU stay. Results showed no significant difference between both reversal groups (SMD: -0.19, 95% CI: -0.54 to 0.17, P = .30, $I^2 = 56\%$) (Fig. 2e).

3.7. Duration of chest tube insertion

Analysis of the 2 studies that reported the duration of chest tube insertion indicated no significant difference between both reversal groups (SMD: -0.43; 95% CI: -1.33 to 0.47, P = .35, $I^2 = 84\%$) (Fig. 2f).

3.8. Sensitivity analysis for incidence of postoperative pulmonary complications

We also conducted sensitivity analyses by excluding the three retrospective studies included for this review. Then, sensitivity analysis for the remaining four prospective studies regarding the incidence of PPCs was conducted (OR 0.42, 95% CI: 0.25–0.71, P = .001, $I^2 = 0\%$). Results showed a similar incidence to the

										Outcomes	mes
Authors & yr	Journal	Country	Study design	Comparison	z	Female (%)	Age, mean ± SD	BMI, mean ± SD	Surgery	PPC evaluation parameters	Others
Cho HC, 2017 ⁽¹⁸⁾	Korean Journal of Anesthe- siology	Korea	Retrospective cohort study	Sugammadex Pyridostigmine	19 31	47.4 48.4	62.7 ± 8.3 61.2 ± 11.8	23.7 ± 3.7 23.7 ± 3.0	VATS lobectomy	Atelectasis, prolonged air Ieak, pneumonia	LOS, duration of chest tube insertion, length of ICU stay
çitil AB, 2019 ⁽¹⁹⁾	Journal of cardiovascular- thoracic anesthesia and intensive care society	Turkey	Parallel RCT	Sugammadex Neostigmine	30 30	33.3 36.7	51 ± 10.2 52 ± 9.6	23 ± 4.0 23 ± 3.0	Lobectomy, pneumectomy, wedge	Atelectasis, pneumonia	Extubation time, total rocuronium dose, length of ICU stay
Lee DK, 2020 ^[20]	Turkish Journal of Medical Sciences	Korea	Retrospective cohort study	Sugammadex Pyridostigmine	90 69	33.3 27.5	59.5 ± 9.5 59.7 ± 9.2	23.16 ± 3.23 23.14 ± 2.99	VATS lobectomy	Early post-operative chest radiographic abnormalities	Extubation time, total rocuronium dose
Lee TY, 2020 ^[21]	Anesth Pain Med	Korea	Parallel RCT	Sugammadex Neostigmine	46 47	34.8 46.8	63.8 ± 9.7 65.5 ± 8.6	25.5 ± 3.6 24.1 ± 3.3	VATS lobectomy	Atelectasis, prolonged air leak, Pneurnonia, desaturation, reintu- bation	LOS, total rocuronium dose, duration of chest tube insertion, length of ICU stay
Moon TS, 2020 ⁽²²⁾	Journal of Clinical Anes- thesia	USA	Parallel RCT	Sugammadex Neostigmine	44 48	50.0 45.8	53.1 ± 14.4 49.9 ± 13.8	*28.4 (25.1–31.0) *30.4 (24.6–35.1)	VATS lobectomy, wedge, others	Post-operative hypoxic episodes	Extubation time, total rocuronium dose, length of PACU stay
Murphy GS, 2021 ¹¹²	Anesthetic Clinical Phar- macology	NSA	NRCT	Sugammadex Neostigmine	97 100	61.9 65.0	68 ± 12 63 ± 13	**77 ± 20/ ***168 ± 10 **75 ± 18/ ***168 ± 11	VATS	Post-operative hypoxic episodes, incidence of residual neuromuscu- lar blockade	Extubation time, total rocuronium dose
Song SW, 2021 ^[23]	Journal of Cardiothoracic Surgery	Korea	Retrospective observational study	Sugammadex Pyridostigmine	127 127	24.4 27.6	*67.0 (60.0–72.0) *66.0 (59.5–71.0)	*23.5 (21.3–25.7) *23.1 (21.5–25.5)	Lobectomy	Atelectasis	LOS, length of PACU stay

Note. BMI = body mass i thoracic surgery. **Neight; ***Height.

Medicine

Table 1

Table 2

Modified Jadad scores of the included studies.

Included studies	a. Was the study described as randomized?	b. Was the method of randomization appropriate?	c. Was the study described as blinding?*	d. Was the method of blinding appropriate?	e. Was there a description of withdrawals and dropouts?	f. Was there a clear description of the inclusion and exclusion criteria?	g. Was the method used to assess adverse effects described?	h. Were the methods of statistical analysis described?	Total
Cho HC, 2017 ^[18]	0	0	0	0	1	1	1	1	4
Çitil AB, 2019 ^[19]	1	1	1	1	1	1	1	1	8
Lee DK, 2020 ^[20]	0	0	1	0	1	1	1	1	5
Lee TY, 2020 ^[21]	1	1	1	1	1	1	1	1	8
Moon TS, 2020 ^[22]	1	1	1	1	1	1	1	1	8
Murphy GS, 2021 ^[12]	0	0	0	0	1	1	1	1	4
Song SW, 2021 ^[23]	0	0	0	0	1	1	1	1	4

Note: a, e, f, g, h: Yes: +1, No: 0; b, d: Yes: +1, No: -1, Not described: 0; c: double-blind: +1; single-blind: +0.5, No: 0.

The total score for each article ranged from 0 to 8; a score of 7 or 8 was considered to be of high quality, 4 to 6 of moderate quality and 1 to 3 of low quality.

postoperative pu	Imonany a	omplice	ations						
		omplica nmade:		Contro	N.		-	dds Ratio	Odds Ratio
Study or Subgrou						Weight		Random, 95% CI	M-H, Random, 95% CI
Cho HC, 2017		2	19	11	31	4.0%		0.21 [0.04, 1.10]	
Çitil AB, 2019			30	2	30	1.8%		0.48 [0.04, 5.63]	
Lee DK, 2020	2	4	90	30	69	24.3%		0.47 [0.24, 0.92]	
Lee TY, 2020			46	14	47	11.1%		0.50 [0.19, 1.33]	
Moon TS, 2020	1	8	44	26	48	15.8%		0.59 [0.26, 1.34]	
Murphy GS, 2021	7	6	97	94	100	11.8%		0.23 [0.09, 0.60]	
Song SW, 2021	2	3 1	27	38	127	31.1%		0.52 [0.29, 0.93]	
Total (95% CI)		4	53		452	100.0%		0.45 [0.32, 0.63]	•
Total events	15			215					
Heterogeneity: Tau					0.76);	$1^2 = 0\%$		0.0	1 0.1 1 10 100
Test for overall effe	ect: Z = 4.75	5 (P < 0.	.00001	1)					ours [sugammadex] Favours [neostigmine]
B length of hospita	l stay (day)							
		ammad	ex	C	ontrol			Std. Mean Differenc	e Std. Mean Difference
Study or Subgrou			Total	Mean	SD	Total	Weight	IV, Random, 95%	
Cho HC, 2017	8.67		19	10		31	27.4%	-0.88 [-1.48, -0.2	
Lee TY, 2020	8.33		46		2.96	47	33.8%	0.25 [-0.16, 0.6	
Song SW, 2021	11		127			127	38.8%	-0.32 [-0.57, -0.0	
Total (95% CI)			192				100.0%	-0.28 [-0.81, 0.2	5]
Heterogeneity: Tau				= 2 (P	= 0.006	5); l ² = 8	1%		-2 -1 0 1
Test for overall effe	ect: Z = 1.05	5 (P = 0	.29)						Favours [sugammadex] Favours [neosti
	(min)								
C extubation time ((min)								
	suga	ammade	ex	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	p Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95%	
Çitil AB, 2019	7.6	4.6	30	26.2	8.3	30	21.9%	-2.74 [-3.45, -2.0	
Lee DK, 2020	8		90	9.33	7.41	69	26.3%	-0.21 [-0.53, 0.1	
Moon TS, 2020	7.33		44	11	8.15	48	25.4%	-0.53 [-0.94, -0.1	
Murphy GS, 2021	9	7	97	15	7	100	26.5%	-0.85 [-1.15, -0.5	6]
Total (95% CI)			261			247	100.0%	1011174 02	
Total (95% CI)	3 - 0 50: 01	12 - 42	261	- 2 /D	0.000		100.0%	-1.01 [-1.74, -0.2	B]
Heterogeneity: Tau			.04, df	= 3 (P •	< 0.000			-1.01 [-1.74, -0.2	-4 -2 0 2
			.04, df	= 3 (P •	< 0.000			-1.01 [-1.74, -0.2	
Heterogeneity: Tau	ect: Z = 2.72		.04, df	= 3 (P ·	< 0.000			-1.01 [-1.74, -0.2	-4 -2 0 2
Heterogeneity: Tau Test for overall effe	ect: Z = 2.72	2 (P = 0.	.04, df .007)		< 0.000			-1.01 [-1.74, -0.2 Std. Mean Differenc	- + + + + -4 -2 0 2 Favours [sugammadex] Favours [neosti
Heterogeneity: Tau Test for overall effe	ect: Z = 2.72	2 (P = 0.	.04, df .007)			001); i² =			e Std. Mean Difference
Heterogeneity: Tau Test for overall effe D rocuronium dose	ect: Z = 2.72 e (mg) sugan	2 (P = 0.	.04, df .007)	с	ontrol	001); i² =	93%	Std. Mean Differenc	
Heterogeneity: Tau Test for overall effe D rocuronium dose Study or Subgroup	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7	2 (P = 0. nmadex SD 1	.04, df .007) Total 30	C <u>Mean</u> 98.6	ontrol SD	001); I ² = Total	93% Weight	Std. Mean Differenc	
Heterogeneity: Tau Test for overall effe D rocuronium dose Study or Subgroup Çitil AB, 2019	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7 120	2 (P = 0. mmadex SD 1 32.4	.04, df .007) .007) 	C Mean 98.6 89.17	ontrol SD 30.1	001); I ² = <u>Total</u> 30	93% Weight 18.0%	Std. Mean Differenc IV. Random. 95% 0.26 [-0.25, 0.7	
Heterogeneity: Tau Test for overall effe Drocuronium dose Study or Subgroup Çitil AB, 2019 Lee DK, 2020 Lee TY, 2020 Moon TS, 2020	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7 120 2 0.156 (103.67 2	2 (P = 0. mmadex <u>SD</u> 32.4 29.63 0.054 26.67	.04, df .007) Total 30 90 46 44	C 98.6 89.17 0.158 106	ontrol SD 30.1 27.78 0.063 37.04	001); I ² = Total 30 69 47 48	93% Weight 18.0% 20.9% 19.7% 19.7%	Std. Mean Difference IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3	e Std. Mean Difference CI IV. Random. 95% CI 6]
Heterogeneity: Tau Test for overall effe Drocuronium dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Lee TY, 2020	ect: Z = 2.72 e (mg) sugan Mean 106.7 120 2 0.156 (2 (P = 0. mmadex <u>SD</u> 32.4 29.63 0.054 26.67	.04, df .007) Total 30 90 46 44	C 98.6 89.17 0.158 106	ontrol SD 30.1 27.78 0.063	001); l ² = Total 30 69 47	93% Weight 18.0% 20.9% 19.7%	Std. Mean Differenc IV. Random. 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3	e Std. Mean Difference CI IV. Random. 95% CI 6]
Heterogeneity: Tau Test for overall effe rocuronium dose <u>Study or Subaroup</u> Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Moon TS, 2020 Murphy GS, 2021	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7 120 2 0.156 (103.67 2	2 (P = 0. mmadex <u>SD</u> 32.4 29.63 0.054 26.67	04, df .007) Total 30 90 46 44 97	C 98.6 89.17 0.158 106	ontrol SD 30.1 27.78 0.063 37.04	Total 30 69 47 48 100	93% Weight 18.0% 20.9% 19.7% 19.7% 21.7%	Std. Mean Difference IV. Random. 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8	e Std. Mean Difference CI IV. Random. 95% CI 6] 9]
Heterogeneity: Tau Test for overall effe D rocuronlum dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% CI)	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7 120 2 0.156 (103.67 73.33	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 0.054 26.67 37.04	04, df .007) Total 30 90 46 44 97 307	C 98.6 89.17 0.158 106 55.42	ontrol SD 30.1 27.78 0.063 37.04 19.44	Total 30 69 47 48 100 294	93% Weight 18.0% 20.9% 19.7% 19.7% 21.7%	Std. Mean Difference IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3	e Std. Mean Difference CI IV. Random. 95% CI 6] 9]
Heterogeneity: Tau Test for overall effe rocuronium dose Study or Subaroup Çitil AB, 2019 Lee DK, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² =	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7 120 2 0.156 (103.67 2 73.33 2 0.20; Chi ²	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 0.054 26.67 37.04 = 26.22,	.04, df .007) Total 30 90 46 44 97 307 , df = 4	C 98.6 89.17 0.158 106 55.42	ontrol SD 30.1 27.78 0.063 37.04 19.44	Total 30 69 47 48 100 294	93% Weight 18.0% 20.9% 19.7% 19.7% 21.7%	Std. Mean Difference IV. Random. 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8	e Std. Mean Difference IV. Random, 55% CI 6] 7] 4] 4] -1 -0.5 0 0.5 1
Heterogeneity: Tau Test for overall effe D rocuronlum dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% CI)	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7 120 2 0.156 (103.67 2 73.33 2 0.20; Chi ²	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 0.054 26.67 37.04 = 26.22,	.04, df .007) Total 30 90 46 44 97 307 , df = 4	C 98.6 89.17 0.158 106 55.42	ontrol SD 30.1 27.78 0.063 37.04 19.44	Total 30 69 47 48 100 294	93% Weight 18.0% 20.9% 19.7% 19.7% 21.7%	Std. Mean Difference IV. Random. 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8	e Std. Mean Difference CI IV. Random. 95% CI 6] 9] 1]
Heterogeneity: Tau Test for overall effe Trocuronium dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Moon TS, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% c1) Heterogeneity: Tau ² = Test for overall effect:	ect: Z = 2.72 (mg) sugan 106.7 120 2 0.156 (103.67 2 73.33 3 0.20; Chi ² : Z = 1.72 (F	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 0.054 26.67 37.04 = 26.22,	.04, df .007) Total 30 90 46 44 97 307 , df = 4	C 98.6 89.17 0.158 106 55.42	ontrol SD 30.1 27.78 0.063 37.04 19.44	Total 30 69 47 48 100 294	93% Weight 18.0% 20.9% 19.7% 19.7% 21.7%	Std. Mean Difference IV. Random. 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8	e Std. Mean Difference IV. Random, 55% CI 6] 7] 4] 4] -1 -0.5 0 0.5 1
Heterogeneity: Tau Test for overall effe rocuronium dose Study or Subaroup Çitil AB, 2019 Lee DK, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² =	ect: Z = 2.72 e (mg) sugan <u>Mean</u> 106.7 100.67 103.67 73.33 0.20; Chi ² Z = 1.72 (F tay (min)	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 0.054 26.67 37.04 = 26.22, P = 0.09	04, df .007) Total 30 90 46 44 97 307 , df = 4	C 98.6 89.17 0.158 106 55.42	ontrol SD 30.1 27.78 0.063 37.04 19.44 0001);	Total 30 69 47 48 100 294	93% Weight 18.0% 20.9% 19.7% 19.7% 21.7%	Std. Mean Difference IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8	A construction of the second s
Heterogeneity: Tau Test for overall effe Trocuronium dose Study or Subaroup Cilii AB, 2019 Lee DK, 2020 Lee TY, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s	ect: Z = 2.72 (mg) sugan <u>Mean</u> 106.7 120 2 0.156 (103.67 2 73.33 3 0.20; ChP Z = 1.72 (F tay (min) sugan	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 0.054 26.67 37.04 = 26.22 P = 0.09 mmadex	30 90 46 44 97 307 , df = 4	C 98.6 89.17 0.158 106 55.42 4 (P < 0.	ontrol SD 30.1 27.78 0.063 37.04 19.44 0001);	Total 30 69 47 48 100 294	93% 18.0% 20.9% 19.7% 21.7% 100.0%	Std. Mean Difference IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 14 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference	e Std. Mean Difference Favours [sugammadex] Favours [neosti e Std. Mean Difference IV. Random. 95% CI favours [sugammadex] Favours [neosti e Std. Mean Difference
Heterogeneity: Tau Test for overall effe D rocuronium dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² Test for overall effect: E length of PACU s Study or Subgroup	ect: Z = 2.72 (mg) sugam <u>Mean</u> 106.7 120 2 0.105.6 0.105.6 0.20; Chi ² : Z = 1.72 (F tay (min) sugar <u>Mean</u>	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 0.054 26.67 37.04 = 26.22, P = 0.09 mmadex <u>SD 1</u>	30 90 46 44 97 307 , df = 4	C 98.6 89.17 0.158 106 55.42 4 (P < 0. C Mean	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 00001); sD	Total 30 69 48 100 294 1 ² = 85 ⁹ Total	Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight	Std. Mean Differenc IV. Random. 95% 0.26 [-0.25, 0.7 1.06 [0.73, 14 -0.03 [-0.44, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Differenc IV. Random. 95%	e Std. Mean Difference GI IV. Random. 95% CI Favours [sugammadex] Favours [neosting 1] -1 -0.5 0 0.5 1 Favours [sugammadex] Favours [neosting 2] Favours [sugammadex] Favours [neosting 2] Std. Mean Difference CI IV. Random. 95% CI
Heterogeneity: Tau Test for overall effe Trocuronium dose Study or Subgroup Gitil AB, 2019 Lee DK, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Study or Subgroup Moon TS, 2020	ect: Z = 2.72 (mg) sugam <u>Mean</u> 106.7 120 2 0.156 (103.67 2 73.33 3 0.20; ChP 3 Z = 1.72 (F tay (min) sugar <u>Mean</u> 144 9	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 20.65 26.67 37.04 = 26.22, P = 0.09 mmadex <u>SD 1</u> 98.52	30 7 30 90 46 44 97 307 , df = 4) K	C 98.6 89.17 0.158 106 55.42 4 (P < 0. C <u>Mean</u> 141	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 0001); control <u>SD</u> 83.7	Total 30 69 47 8 100 294 1 ² = 859 Total 48	93% Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight 39.9%	Std. Mean Difference IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference IV. Random, 95% 0.03 [-0.38, 0.4	A constraints of the second seco
Heterogeneity: Tau Test for overall effe D rocuronium dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² Test for overall effect: E length of PACU s Study or Subgroup	ect: Z = 2.72 (mg) sugam <u>Mean</u> 106.7 120 2 0.105.6 0.105.6 0.20; Chi ² : Z = 1.72 (F tay (min) sugar <u>Mean</u>	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 20.65 26.67 37.04 = 26.22, P = 0.09 mmadex <u>SD 1</u> 98.52	30 7 30 90 46 44 97 307 , df = 4) K	C 98.6 89.17 0.158 106 55.42 4 (P < 0. C <u>Mean</u> 141	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 00001); sD	Total 30 69 48 100 294 1 ² = 85 ⁹ Total	Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight	Std. Mean Differenc IV. Random. 95% 0.26 [-0.25, 0.7 1.06 [0.73, 14 -0.03 [-0.44, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Differenc IV. Random. 95%	A constraints of the second seco
Heterogeneity: Tau Test for overall effe D rocuronium dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Moon TS, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Study or Subgroup Moon TS, 2020 Song SW, 2021	ect: Z = 2.72 (mg) sugam <u>Mean</u> 106.7 120 2 0.156 (103.67 2 73.33 3 0.20; ChP 3 Z = 1.72 (F tay (min) sugar <u>Mean</u> 144 9	2 (P = 0. mmadex <u>SD 1</u> 32.4 29.63 20.65 26.67 37.04 = 26.22, P = 0.09 mmadex <u>SD 1</u> 98.52	(x) (04, df (x) (007) (x) (x) (x) (x) (x) (x) (x) (x) (x) (x)	C 98.6 89.17 0.158 106 55.42 4 (P < 0. C <u>Mean</u> 141	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 0001); control <u>SD</u> 83.7	Total 30 69 47 48 100 294 1 ² = 859 Total 48 127	93% Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight 39.9% 60.1%	Std. Mean Difference V. Random, 95% 0.26 [-0.25, 0.7] 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference V. Random, 95% 0.03 [-0.38, 0.4 -0.34 [-0.58, -0.0	A constraints of the second se
Heterogeneity: Tau Test for overall effe D rocuronlum dose Study or Subaroup Citil AB, 2019 Lee DK, 2020 Lee DK, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Study or Subaroup Moon TS, 2020 Song SW, 2021 Total (95% CI)	ect: Z = 2.72 (mg) sugan <u>Mean</u> 106.7 120.2 0.156 (103.67 73.33 0.20; ChP Z = 1.72 (F tay (min) sugan <u>Mean</u> 144 (63.33	P = 0.000 + 0.00000 + 0.000000 + 0.000000 + 0.00000 + 0.0000 + 0.0000 + 0.0000 + 0	(1) (1) (1) (1) (1) (1) (1) (1)	C Mean 98.6 89.17 106 55.42 4 (P < 0. C C Mean 141 68.33	ontrol 30.1 27.78 0.063 37.04 19.44 00001); 00001); 83.7 14.81	Total 30 69 47 48 100 294 1 ² = 85 ⁶ 12 ² = 85 ⁶ 127 48 127	93% Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight 39.9%	Std. Mean Difference V. Random, 95% 0.26 [-0.25, 0.7] 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference V. Random, 95% 0.03 [-0.38, 0.4 -0.34 [-0.58, -0.0	A constraints of the second se
Heterogeneity: Tau Test for overall effe D rocuronium dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Sudy or Subgroup Moon TS, 2020 Song SW, 2021 Total (95% CI) Heterogeneity: Tau ²	ect: Z = 2.72 (mg) sugan 106.7 120 2 0.156 (103.67 2 73.33 2 0.20; Chi ² 3 Z = 1.72 (F tay (min) sugar 144 9 63.33 2 = 0.04; Chi ²	2 (P = 0. mmadexx <u>SD</u> 1 32.4 29.63 0.054 26.67 37.04 = 26.22 P = 0.09 mmadex <u>SD</u> 1 98.52 14.81 = 2.29,	(1) (1) (1) (1) (1) (1) (1) (1)	C Mean 98.6 89.17 106 55.42 4 (P < 0. C C Mean 141 68.33	ontrol 30.1 27.78 0.063 37.04 19.44 00001); 00001); 83.7 14.81	Total 30 69 47 48 100 294 1 ² = 85 ⁶ 12 ² = 85 ⁶ 127 48 127	93% Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight 39.9% 60.1%	Std. Mean Difference V. Random, 95% 0.26 [-0.25, 0.7] 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference V. Random, 95% 0.03 [-0.38, 0.4 -0.34 [-0.58, -0.0	Std. Mean Difference IV. Random, 95% CI Favours [sugammadex] Favours [neostil IV. Random, 95% CI
Heterogeneity: Tau Test for overall effe D rocuronlum dose Study or Subaroup Citil AB, 2019 Lee DK, 2020 Lee DK, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Study or Subaroup Moon TS, 2020 Song SW, 2021 Total (95% CI)	ect: Z = 2.72 (mg) sugan 106.7 120 2 0.156 (103.67 2 73.33 2 0.20; Chi ² 3 Z = 1.72 (F tay (min) sugar 144 9 63.33 2 = 0.04; Chi ²	2 (P = 0. mmadexx <u>SD</u> 1 32.4 29.63 0.054 26.67 37.04 = 26.22 P = 0.09 mmadex <u>SD</u> 1 98.52 14.81 = 2.29,	(1) (1) (1) (1) (1) (1) (1) (1)	C Mean 98.6 89.17 106 55.42 4 (P < 0. C C Mean 141 68.33	ontrol 30.1 27.78 0.063 37.04 19.44 00001); 00001); 83.7 14.81	Total 30 69 47 48 100 294 1 ² = 85 ⁶ 12 ² = 85 ⁶ 127 48 127	93% Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight 39.9% 60.1%	Std. Mean Difference V. Random, 95% 0.26 [-0.25, 0.7] 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference V. Random, 95% 0.03 [-0.38, 0.4 -0.34 [-0.58, -0.0	Std. Mean Difference Std. Mean Difference V. Random, 95% CI
Heterogeneity: Tau Test for overall effet Tocuronium dose Study or Subaroup Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Morn TS, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Study or Subaroup Moon TS, 2020 Mon TS, 2020 Song SW, 2021 Total (95% CI) Heterogeneity: Tau ³ =	ett: Z = 2.72 (mg) sugan 106.7 120 : 0.156 (103.67 : 73.33 : 0.20; ChP z = 1.72 (F tay (min) sugan 144 (63.33 : = 0.04; ChP t: Z = 1.05 (2 (P = 0. mmadexx <u>SD</u> 1 32.4 29.63 0.054 26.67 37.04 = 26.22 P = 0.09 mmadex <u>SD</u> 1 98.52 14.81 = 2.29,	(1) (1) (1) (1) (1) (1) (1) (1)	C Mean 98.6 89.17 106 55.42 4 (P < 0. C C Mean 141 68.33	ontrol 30.1 27.78 0.063 37.04 19.44 00001); 00001); 83.7 14.81	Total 30 69 47 48 100 294 1 ² = 85 ⁶ 12 ² = 85 ⁶ 127 48 127	93% Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight 39.9% 60.1%	Std. Mean Difference V. Random, 95% 0.26 [-0.25, 0.7] 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference V. Random, 95% 0.03 [-0.38, 0.4 -0.34 [-0.58, -0.0	Std. Mean Difference IV. Random, 95% CI Favours [sugammadex] Favours [neostil IV. Random, 95% CI
Heterogeneity: Tau Test for overall effe D rocuronium dose Study or Subgroup Citil AB, 2019 Lee DK, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Sudy or Subgroup Moon TS, 2020 Song SW, 2021 Total (95% CI) Heterogeneity: Tau ²	ett: Z = 2.72 (mg) sugan 106.7 120 : 0.156 (103.67 : 73.33 : 0.20; ChP : Z = 1.72 (F tay (min) sugar 144 : 63.33 : = 0.04; ChP t: Z = 1.05 (ion (day)	2 (P = 0. mmadex <u>SD</u> 1 32.4 29.63 0.054 26.67 37.04 = 26.22, = 0.09 <u>SD</u> 1 98.52 14.81 = 2.29, P = 0.30	0.04, df 0.007) 300 46 44 97 307 , df = 4) x x x x x x x x x x x x x	C Mean 98.6 89.17 106 55.42 4 (P < 0. C Mean 141 68.33 (P = 0.	ontrol SD 30.1 27.78 0.063 37.04 19.44 0001); SD 83.7 14.81 13); I ²	$\frac{\text{Total}}{30}$ $\frac{30}{69}$ 47 48 100 294 $1^2 = 859$ $\frac{1}{27}$ 175 $= 56\%$	93% Weight 18.0% 20.9% 19.7% 21.7% 100.0% 6 Weight 39.9% 60.1%	Std. Mean Difference IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference IV. Random, 95% 0.03 [-0.38, -0.0 -0.34 [-0.58, -0.0 -0.19 [-0.54, 0.1	e Std. Mean Difference IV. Random. 95% CI Favours [sugammadex] Favours [neosting Favours [sugammadex] Favours [neosting Std. Mean Difference IV. Random. 95% CI Favours [sugammadex] Favours [neosting Favours [sugammadex] Favours [neosting] Favours [sugammadex] Favours [neosting]
Heterogeneity: Tau Test for overall effe Current of the second Gill AB, 2019 Lee DK, 2020 Murphy GS, 2021 Heterogeneity: Tau ² = Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Study or Subgroup Moon TS, 2020 Song SW, 2021 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect F chest tube insertit	ett: Z = 2.72 (mg) sugar 106.7 120.2 0.156 0.20; ChP + Z = 1.72 (F tay (min) sugar Mean 144 (63.33 - 144 (144 (144 (145 (145 (147 (2 (P = 0.) mmadex <u>SD</u> 1 32.4 29.63 0.054 26.67 37.04 = 26.22, P = 0.09 <u>SD</u> 1 98.52 14.81 = 2.29,9 P = 0.30	(c)	C Mean 98.6 89.17 106 55.42 4 (P < 0. Mean 141 68.33 (P = 0. C	oontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 00011); <u>SD</u> 83.7 14.81 13); I ² oontrol	Total 30 69 47 48 100 294 1 ² = 859 Total 48 127 175 = 56%	93% Weight 18.0% 20.9% 19.7% 19.7% 21.7% 100.0% 6 Weight 100.0%	Std. Mean Differenci IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Differenci IV. Random, 95% 0.03 [-0.38, 0.4 -0.34 [-0.58, -0.0 -0.19 [-0.54, 0.1 Std. Mean Differenci	A std. Mean Difference CI IV. Random. 95% CI Favours [sugammadex] Favours [neosting] Favours [sugammadex] Favours [neosting] Favours [sugammadex] Favours [neosting] CI IV. Random. 95% CI Favours [sugammadex] Favours [neosting] Std. Mean Difference
Heterogeneity: Tau Test for overall effe D rocuronlum dose Study or Subaroup Citil AB, 2019 Lee DK, 2020 Lee DK, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect E length of PACU s Study or Subaroup Moon TS, 2020 Song SW, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect E chest tube insertil Study or Subaroup	ett: Z = 2.72 (mg) sugan Maan 106.7 120.2 0.166 103.67 Z = 1.72 (F tay (min) sugar Maan 144.6 63.33 = 0.04; Chi ² t: Z = 1.05 (ion (Sug) sugar Maan 145.6 1	2 (P = 0. mmadex <u>SD</u> 1 32.4 29.63 37.04 = 26.22, = 0.09 mmadex <u>SD</u> 1 98.52 14.81 = 2.29, P = 0.30 <u>SD</u> 2.22 = 0.30 <u>SD</u> 1 = 2.29, SD 2 = 0.30	Code, df Total 30 90 46 44 97 307 df = 4 97 307 df = 4 127 171 df = 1 0) Example 2 Example 2	C Mean 98.6 89.17 106 55.42 4 (P < 0. C Mean 141 68.33 (P = 0. C Mean	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 00011); <u>SD</u> 83.7 14.81 13); I ² ontrol <u>SD</u>	Total 300 69 47 48 100 294 1 ² = 85 ⁹ Total 48 127 175 = 56% Total	93% Weight 18.0% 19.7% 19.7% 21.7% 6 100.0% 6	Std. Mean Differenci IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Differenci IV. Random, 95% Std. Mean Differenci IV. Random, 95%	Std. Mean Difference Std. Mean Difference Std. Mean Difference IV. Random, 95% CI
Heterogeneity: Tau Test for overall effet D rocuronium dose Study or Subgroup C(ill AB, 2019 Lee DK, 2020 Lee TY, 2020 Morn TS, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Moon TS, 2020 Song SW, 2021 Total (95% CI) Heterogeneity: Tau ² Total (95% CI) Heterogeneity: Tau ² Total (95% CI) Heterogeneity: Tau ² Cho HC, 2017	ett: Z = 2.72 (mg) sugar 106.7 120.2 0.156 (103.67 Z = 1.72 (F tay (min) sugar 144 63.33 = 0.04; Chi ² t: Z = 1.05 (ion (day) sugar 5.33	2 (P = 0. mmadex <u>SD</u> 1 32.4 29.63 0.054 26.67 37.04 = 26.22, = 0.09 <u>SD</u> 1 98.52 14.81 = 2.29, P = 0.30 <u>SD</u> 2.22	(1004, df (1004, df (1004, df (1004, df (1004) (1	C Mean 98.6 89.17 106 55.42 4 (P < 0. C Mean 141 68.33 (P = 0. C Mean 7 7	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 00001); <u>SD</u> 83.7 14.81 13); I ² ontrol <u>SD</u> 1.48	Total 30 69 47 48 100 294 1 ² = 859 170tal 175 = 56%	93% Weight 100.0% Weight 100.0% Weight 47.0%	Std. Mean Differenci IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Differenci IV. Random, 95% -0.34 [-0.58, -0.0 -0.19 [-0.54, 0.1 Std. Mean Differenci IV. Random, 95% -0.92 [-1.52, -0.3	e Std. Mean Difference CI IV. Random. 95% CI 6 6 71 11 -1 Favours [sugammadex] Favours [neosting 6 11 -1 -0.5 0 0.5 11 -1 -0.5 0 0.5 15 Favours [neosting 12 -1 -0.5 0 0.5 15 Favours [neosting 13 -1 -1 -0.5 0 0.5 15 Favours [neosting 14 19 10 -1 -1 -0.5 0 0.5 15 Favours [neosting 15 -1 -1 -0.5 0 0.5 15 Favours [neosting 15 -1 -1 -1 -0.5 0 0.5 15 Favours [neosting 15 -1 -1 -1 -1 -0.5 0 0 -1 -1 -1 -1 -1 -1 -0.5 0 0 -5 -1 -1 -1 -1 -0.5 0 0 -5 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Heterogeneity: Tau Test for overall effe D rocuronlum dose Study or Subaroup Citil AB, 2019 Lee DK, 2020 Lee DK, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect E length of PACU s Study or Subaroup Moon TS, 2020 Song SW, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect E chest tube insertil Study or Subaroup	ett: Z = 2.72 (mg) sugan Maan 106.7 120.2 0.166 103.67 Z = 1.72 (F tay (min) sugar Maan 144.6 63.33 = 0.04; Chi ² t: Z = 1.05 (ion (Sug) sugar Maan 145.6 1	2 (P = 0. mmadex <u>SD</u> 1 32.4 29.63 37.04 = 26.22, = 0.09 mmadex <u>SD</u> 1 98.52 14.81 = 2.29, P = 0.30 <u>SD</u> 2.22 = 0.30 <u>SD</u> 1 = 2.29, SD 2 = 0.30	Code, df Total 30 90 46 44 97 307 df = 4 97 307 df = 4 127 171 df = 1 0) Example 2 Example 2	C Mean 98.6 89.17 106 55.42 4 (P < 0. C Mean 141 68.33 (P = 0. C Mean 7 7	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 00011); <u>SD</u> 83.7 14.81 13); I ² ontrol <u>SD</u>	Total 300 69 47 48 100 294 1 ² = 85 ⁹ Total 48 127 175 = 56% Total	93% Weight 18.0% 19.7% 19.7% 21.7% 6 100.0% 6	Std. Mean Differenci IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Differenci IV. Random, 95% Std. Mean Differenci IV. Random, 95%	e Std. Mean Difference CI IV. Random. 95% CI 6 6 71 11 -1 Favours [sugammadex] Favours [neosting 6 11 -1 -0.5 0 0.5 11 -1 -0.5 0 0.5 15 Favours [neosting 12 -1 -0.5 0 0.5 15 Favours [neosting 13 -1 -1 -0.5 0 0.5 15 Favours [neosting 14 19 10 -1 -1 -0.5 0 0.5 15 Favours [neosting 15 -1 -1 -0.5 0 0.5 15 Favours [neosting 15 -1 -1 -1 -0.5 0 0.5 15 Favours [neosting 15 -1 -1 -1 -1 -0.5 0 0 -1 -1 -1 -1 -1 -1 -0.5 0 0 -5 -1 -1 -1 -1 -0.5 0 0 -5 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Heterogeneity: Tau Test for overall effe Tocuronium dose Study or Subaroup Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: E length of PACU s Study or Subaroup Moon TS, 2020 Moon TS, 2020 Moon TS, 2020 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect F chest tube insertit Study or Subaroun Cho HC, 2017 Lee TY, 2020	ett: Z = 2.72 (mg) sugar 106.7 120.2 0.156 (103.67 Z = 1.72 (F tay (min) sugar 144 63.33 = 0.04; Chi ² t: Z = 1.05 (ion (day) sugar 5.33	2 (P = 0. mmadex <u>SD</u> 1 32.4 29.63 0.054 26.67 37.04 = 26.22, = 0.09 <u>SD</u> 1 98.52 14.81 = 2.29, P = 0.30 <u>SD</u> 2.22	(004, df 30 90 46 44 97 307 df = 4 127 171 44 127 171 df = 1 0) ex Total 19 46	C Mean 98.6 89.17 106 55.42 4 (P < 0. C Mean 141 68.33 (P = 0. C Mean 7 7	ontrol <u>SD</u> 30.1 27.78 0.063 37.04 19.44 00001); <u>SD</u> 83.7 14.81 13); I ² ontrol <u>SD</u> 1.48	Total 30 30 30 69 47 48 100 294 1 ² = 85 ⁹ 170 175 = 56% Total 31 47	Weight 18.0% 20.9% 19.7% 21.7% 100.0% Weight 100.0% Weight 47.0% 53.0%	Std. Mean Differenci IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Difference IV. Random, 95% 0.03 [-0.38, 0.4 -0.19 [-0.54, 0.1 Std. Mean Difference IV. Random, 95% -0.92 [-1.52, -0.3 0.00 [-0.41, 0.4	e Std. Mean Difference Cl IV. Random, 95% Cl Favours [sugammadex] Favours [neosting Cl IV. Random, 95% Cl Favours [sugammadex] Favours [neosting Std. Mean Difference Cl IV. Random, 95% Cl Std. Mean Difference Std. Mean Difference Cl IV. Random, 95% Cl Std. Mean Difference Std. Mean Difference
Heterogeneity: Tau Test for overall effet Citil AB, 2019 Lee DK, 2020 Lee TY, 2020 Murphy GS, 2021 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect E length of PACU s Study or Subgroup Moon TS, 2020 Song SW, 2021 Total (95% CI) Heterogeneity: Tau ² = Study or Subgroup Cho HC, 2017	ett: Z = 2.72 (mg) sugar 106.7 120 2 0.156 0 103.67 2 73.33 2 0.20; Ch ² 2 7.33 3 0.20; Ch ² 4 Z = 1.72 (F tay (min) sugar 144 9 63.33 2 = 0.04; Ch ² 4 t: Z = 1.05 (tion (day) sugar 5.33 2.33	2 (P = 0. mmadex <u>SD 1</u> 32.4 26.67 37.04 = 26.22, P = 0.09 mmadex <u>SD 1</u> 98.52 44.81 = 2.29, P = 0.3(<u>SD 2.22 0.74 </u>	(x) (x) (x) (x) (x) (x) (x) (x)	C Mean 98.6 89.17 106 55.42 4 (P < 0. C Mean 141 68.33 (P = 0. (P = 0. 7 2.33	ontrol 30.1 27.78 30.0 37.04 19.44 00001); 83.7 14.81 13); I ² 13); I ² 1.4.8 0.74	Total 30 69 47 48 100 294 47 8 100 294 48 127 175 = 56% Total 31 47 78	93% Weighti 18.0% 20.9% 19.7% 19.7% 21.7% 100.0% 60.1% 100.0% Weighti 47.0% 53.0%	Std. Mean Differenci IV. Random, 95% 0.26 [-0.25, 0.7 1.06 [0.73, 1.4 -0.03 [-0.44, 0.3 -0.07 [-0.48, 0.3 0.61 [0.32, 0.8 0.38 [-0.05, 0.8 Std. Mean Differenci IV. Random, 95% -0.34 [-0.58, -0.0 -0.19 [-0.54, 0.1 Std. Mean Differenci IV. Random, 95% -0.92 [-1.52, -0.3	e Std. Mean Difference Cl IV. Random, 95% Cl Favours [sugammadex] Favours [neosting Cl IV. Random, 95% Cl Favours [sugammadex] Favours [neosting Std. Mean Difference Cl IV. Random, 95% Cl Std. Mean Difference Std. Mean Difference Cl IV. Random, 95% Cl Std. Mean Difference Std. Mean Difference

Figure 2. Forest plots comparing sugammadex use versus control on (a) postoperative pulmonary complications; (b) length of hospital stay (days); (c) total rocuronium dose (mg); (d) extubation time (minutes); (e) length of PACU stay (minutes); (f) duration of chest tube insertion (days).

Results of subgroup	meta-analysis o	f post-operative	pulmonary	complications.

			95% confidence interval		
	Subgroups	Odds ratio	Lower limit	Upper limit	P value
PPCs assessment parameters	Atelectasis mainly Early post-operative chest radiographic abnormalities, incidence of post-operative hypoxic episodes and residual neuromuscular blockade	0.47 0.43	0.3 0.26	0.76 0.69	.002 .0006
BMI	≥ 25 <25	0.42 0.47	0.24 0.31	0.73 0.72	.002 .0004

BMI = body mass index, PPCs = post-operative pulmonary complication.

main analysis (OR 0.45, 95% CI: 0.32–0.63, P < .001, $I^2 = 0\%$), indicating that the main result was robust.

4. Discussion

This meta-analysis observed that sugammadex administration after lung surgery decreased the incidence of PPCs. We also demonstrated that although using sugammadex to reverse muscle relaxation after lung surgery was faster, recovery, and extubation times were shorter than using neostigmine. Moreover, LOS, PACU stay length, and chest tube insertion duration had no significant difference.

During noncardiac surgeries, a previous study showed that sugammadex was associated with a 30% reduced risk of PPCs.^[24] In colon surgery, however, no difference in postoperative outcomes with the use of sugammadex was observed.^[25] Based on our extensive literature search, this research is the first meta-analysis to evaluate the effect of sugammadex in lung surgery. In this study, we focused on the population of patients undergoing lung surgery, considered a higher risk of PPCs.^[9] Sugammadex seemed to reduce PPCs without changing the LOS because PPCs were a leading cause of poor surgical outcomes.^[13,26] Therefore, using sugammadex for lung surgery is considered beneficial.

Since no standardized definition of PPC^[5] exists, we integrated them using a standard definition according to Abbott et al ^[27] Then, we conducted a subgroup analysis of atelectasis and non-atelectasis. Results showed that the sugammadex group had a lesser occurrence of atelectasis and non-atelectasis PPCs.

The anesthetic management of obese patients can be challenging because of their altered anatomy and physiology. Studies have reported that approximately 18% of obese patients undergoing surgery experience PPCs, almost twice the risk among average or overweight patients.^[28] A BMI of ≥ 25 was one of the independent risk factors for PPCs in lung cancer patients who underwent VATS lung surgeries.^[29] Notably, our result showed the benefit of reducing the incidence of PPCs using sugammadex in patients who underwent lung surgery in both the high (≥ 25) and low BMI (< 25) groups.

Bradycardia and hypotension induced through sugammadex after VATS surgery have been reported previously.^[30] The mechanism underlying the decrease in heart remained unknown; however, Kounis syndrome or hypersensitivity appeared to be the most plausible mechanism.^[31,32] Both sugammadex and neostigmine were associated with serious adverse events in <1% of patients, and data showed that there was little to no difference in the risk of serious adverse events.^[4,33]. The use of anticholinergic agents including atropine and glycopyrrolate to treat bradycardia, and vasopressors (ephedrine, norepinephrine, and epinephrine) to treat hypotension should be considered. Although sugammadex effectively prevents postoperative residual neuromuscular blockade, anesthesiologists should consider it as a causative agent of cardiac arrest during surgery.

The study's strength was that we focused on lung surgery and analyzed PPCs. Subgroup analysis was also performed for atelectasis and non-atelectasis. Additionally, we conducted another subgroup analysis to examine whether the treatment effect was affected by BMI. Then, we used modified Jadad scores to assess the selected studies' methodological quality, which showed moderate to high-quality results. We also performed a sensitivity analysis by excluding the retrospective studies.

However, several limitations to this study were encountered. First, all included trials showed heterogeneity in the types of lung surgery, the different ranges of lung resection could affect the outcomes.^[29] Second, surgical complications such as massive intraoperative blood loss^[34] were not evaluated in the present study, which could influence the outcome. Third, owing to the fact that the reports included in the present meta-analysis did not include the pertinent information, we did not perform further analysis on the independent risk factors of PPC after VATS surgeries, such as chronic obstructive pulmonary disease,^[35] smoking, preoperative $FEV_1 \le 60\%$, $PaO_2 \le 60 \text{ mm}$ Hg, intraoperative crystalloids $\geq 6 \text{ mL/kg/h}$, duration of surgery ≥ 2 hours.^[9,36-38] Additionally, this study did not analyze some side effects of reversal agents (such as postoperative nausea and vomiting, bradycardia, and so forth).

In conclusion, we observed that although reversal with sugammadex in patients undergoing thoracic VATS surgery had lesser PPCs and shorter extubation periods than other conventional reversal agents, in obese and non-obese patients. No difference was observed between LOS, length of PACU stay and duration of chest tube insertion existed in both groups.

Acknowledgements

The authors would like to thank Enago (www.enago.tw) for the English language review.

Author contributions

Conceptualization, Jia-Li Yang; methodology, Mei-Ling Shen; formal analysis, Wei-Ti Hsu; investigation, Wei-Ti Hsu; resources, Yu-Wen Lai; data curation, Yu-Wen Lai; writing—original draft preparation, Jia-Li Yang; writing—review and editing, Kuen-Bao Chen; supervision, Chieh-Min Hsu. All authors have read and agreed to the published version of the manuscript.

References

- Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015;70:1441–52.
- [2] Abrishami A, Ho J, Wong J, Yin L, et al. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009;110:Cd007362.
- [3] Carron M, Zarantonello F, Lazzarotto N, et al. Role of sugammadex in accelerating postoperative discharge: a meta-analysis. J Clin Anesth. 2017;39:38–44.

- [4] Hristovska AM, Duch P, Allingstrup M, et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8:Cd012763.
- [5] Li G, Freundlich RE, Gupta RK, et al. Postoperative pulmonary complications' association with sugammadex versus neostigmine: a retrospective registry analysis. Anesthesiology. 2021;134:862–73.
- [6] Carron M, Tessari I, Linassi F. Sugammadex compared with neostigmine in reducing postoperative pulmonary complications in older patients: a meta-analysis. Br J Anaesth. 2022;128:e259–62.
- [7] Togioka BM, Yanez D, Aziz MF, et al. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. Br J Anaesth. 2020;124:553–61.
- [8] Guirado M, Fernandez Martin E, Fernandez Villar A, et al. Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review. Clin Transl Oncol. 2022;24:1549–68.
- [9] Lugg ST, Agostini PJ, Tikka T, et al. Long-term impact of developing a postoperative pulmonary complication after lung surgery. Thorax. 2016;71:171–6.
- [10] Serpa Neto A, Hemmes SN, Barbas CS, et al. Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic review and meta-analysis. Lancet Respir Med. 2014;2:1007–15.
- [11] Errando CL, Garutti I, Mazzinari G, et al. Residual neuromuscular blockade in the postanesthesia care unit: observational cross-sectional study of a multicenter cohort. Minerva Anestesiol. 2016;82:1267–77.
- [12] Murphy GS, Avram MJ, Greenberg SB, et al. Neuromuscular and clinical recovery in thoracic surgical patients reversed with neostigmine or sugammadex. Anesth Analg. 2021;133:435–44.
- [13] Fernandez-Bustamante A, Frendl G, Sprung J, et al. Postoperative pulmonary complications, early mortality, and hospital stay following noncardiothoracic surgery: a multicenter study by the perioperative research network investigators. JAMA Surg. 2017;152:157–66.
- [14] Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695–703.
- [15] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clin Res Ed). 2015;349:g7647.
- [16] Oremus M, Wolfson C, Perrault A, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord. 2001;12:232–6.
- [17] Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
- [18] Cho HC, Lee JH, Lee SC, et al. Use of sugammadex in lung cancer patients undergoing video-assisted thoracoscopic lobectomy. Korean J Anesthesiol. 2017;70:420–5.
- [19] Çitil AB, Tuncel ZA, Yapici N, et al. Reversal of rocuronium induced neuromuscular blockade in lung resection surgery: a comparison of sugammadex and neostigmine. Gogus-Kalp-Damar Anestezi ve Yogun Bakim Dernegi Dergisi. 2019;25:23–30.
- [20] Lee DK, Kang SW, Kim HK, et al Effect of sugammadex on chest radiographic abnormality in the early postoperative period after video-assisted thoracoscopic lobectomy. Turk J Med Sci. 2020;50:1236–46.
- [21] Lee TY, Jeong SY, Jeong JH, et al. Comparison of postoperative pulmonary complications between sugammadex and neostigmine in lung cancer patients undergoing video-assisted thoracoscopic lobectomy: a prospective double-blinded randomized trial. Anesth Pain Med. 2021;16:60–7.

- [22] Moon TS, Reznik S, Pak T, et al. Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular blockade: a randomized, double-blinded study of thoracic surgical patients evaluating hypoxic episodes in the early postoperative period. J Clin Anesth. 2020;64:109804.
- [23] Song SW, Yoo KY, Ro YS, et al. Sugammadex is associated with shorter hospital length of stay after open lobectomy for lung cancer: a retrospective observational study. J Cardiothorac Surg. 2021;16:45.
- [24] Kheterpal S, Vaughn MT, Dubovoy TZ, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis. Anesthesiology. 2020;132:1371–81.
- [25] Chen AT, Patel A, McKechnie T, et al. Sugammadex in colorectal surgery: a systematic review and meta-analysis. J Surg Res. 2022;270:221–9.
- [26] Yamamichi T, Ichinose J, Omura K, et al. Impact of postoperative complications on the long-term outcome in lung cancer surgery. Surg Today. 2022;1:18.
- [27] Abbott TEF, Fowler AJ, Pelosi P, et al. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. Br J Anaesth. 2018;120:1066–79.
- [28] Bluth T, Serpa Neto A, Schultz MJ, et al; Effect of intraoperative high positive end-expiratory pressure (PEEP) with recruitment maneuvers vs low PEEP on postoperative pulmonary complications in obese patients: a randomized clinical trial. JAMA. 2019;321:2292–305.
- [29] Yang R, Wu Y, Yao L, et al. Risk factors of postoperative pulmonary complications after minimally invasive anatomic resection for lung cancer. Ther Clin Risk Manag. 2019;15:223–31. Published 2019 Feb 4.
- [30] Teng IC, Chang YJ, Lin YT, et al. Sugammadex induced bradycardia and hypotension: a case report and literature review. Medicine (Baltim). 2021;100:e26796.
- [31] Ebert TJ, Cumming CE, Roberts CJ, et al. Characterizing the heart rate effects from administration of sugammadex to reverse neuromuscular blockade: an observational study in patients. Anesth Analg. 2022;135:807–14.
- [32] Fierro C, Medoro A, Mignogna D, et al. Severe hypotension, bradycardia and asystole after sugammadex administration in an elderly patient. Medicina (Kaunas). 2021;57:79. Published 2021 Jan 19.
- [33] Hristovska AM, Duch P, Allingstrup M, et al. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2018;73:631–41.
- [34] Zhang X, Jin R, Zheng Y, et al. Interactions between the enhanced recovery after surgery pathway and risk factors for lung infections after pulmonary malignancy operation. Transl Lung Cancer Res. 2020;9:1831–42.
- [35] Kim ES, Kim YT, Kang CH, et al. Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1317–26. Published 2016 Jun 16.
- [36] Agostini PJ, Lugg ST, Adams K, et al. Risk factors and short-term outcomes of postoperative pulmonary complications after VATS lobectomy. J Cardiothorac Surg. 2018;13:28. Published 2018 Apr 12.
- [37] Kaufmann KB, Loop T, Heinrich S. et al. Risk factors for post-operative pulmonary complications in lung cancer patients after video-assisted thoracoscopic lung resection: results of the German Thorax Registry. Acta Anaesthesiol Scand. 2019;63:1009–18.
- [38] Arslantas MK, Kara HV, Tuncer BB, et al. Effect of the amount of intraoperative fluid administration on postoperative pulmonary complications following anatomic lung resections. J Thorac Cardiovasc Surg. 2015;149:314–20, 321.e1.